Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADA | P00813 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847280 | 0.95 | ADORA2A (0.50) | ADORA2AHDAC1ADORA3ADORA1ADORA2B | |
| SCHEMBL2848487 | 0.91 | ADORA2A (0.50) | ADORA2AHDAC1ADA | |
| SCHEMBL2846190 | 0.88 | ADORA2A (0.56) | ADORA2AHDAC1ADORA3ADORA1ADORA2B | |
| SCHEMBL13321511 | 0.87 | ADORA2A (0.52) | ADORA2AHDAC1ADORA3ADORA1ADA | |
| SCHEMBL2848249 | 0.87 | ADORA2A (0.49) | ADORA2AHDAC1ADORA3ADORA1ADORA2B | |
| SCHEMBL8152568 | 0.86 | ADORA2A (0.49) | ADORA2AHDAC1ADORA3ADORA1 | |
| SCHEMBL2847263 | 0.85 | ADORA2A (0.49) | ADORA2AHDAC1ADORA3ADORA1 | |
| SCHEMBL4378518 | 0.84 | ADORA2A (0.48) | ADORA2AHDAC1ADORA3ADORA1ADORA2B | |
| SCHEMBL8149397 | 0.83 | ADORA2A (0.49) | ADORA2AHDAC1ADORA3ADORA1ADORA2B | |
| SCHEMBL2853601 | 0.77 | ADORA2A (0.61) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723343-B2 | Adenosine A2A receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-05-25 | — | — | US | claimed |
| EP-2129220-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| WO-2008121748-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT,INC. (US) | 2008-10-09 | — | — | WO | claimed |
| US-20080242673-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-10-02 | — | — | US | claimed |
| US-7723343-B2 | Adenosine A2A receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7691869-B2 | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080242672-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242673-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242672-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885HDAC1 4098/4885ADORA3 4/4885 |
| US-20080242673-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885HDAC1 4098/4885ADORA3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.